NEIL EHRLICH: Open Payments
NPI 1013078625 · SANTA ROSA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$989 in 40 payments from 8 companies in 2025. Trend: 2023 $1,077 · 2024 $1,361 · 2025 $989
Food & beverage: $878Education: $111
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $257 |
| Teva Pharmaceuticals USA, Inc. | 6 | $204 |
| Otsuka America Pharmaceutical, Inc. | 8 | $168 |
| Lundbeck LLC | 5 | $93 |
| Alkermes, Inc. | 4 | $77 |
| E.R. Squibb & Sons, L.L.C. | 3 | $76 |
| ABBVIE INC. | 3 | $60 |
| Neurocrine BioSciences, Inc. | 3 | $55 |
Products named: CAPLYTA, REXULTI, UZEDY, ARISTADA, COBENFY, VRAYLAR, ABILIFY MAINTENA, INGREZZA.
Industry payments across CA — which companies pay providers there.
